Clinical Trial of Cross-linked Hyaluronic Acid Dermal Filler

Maxigen Biotech

Status

Completed

Conditions

Dermal Fillers

Hyaluronic Acid

Treatments

Device: Formaderm Young

Device: Restylane

Study type

Interventional

Funder types

Industry

Identifiers

NCT05935501

MBI-2016-01

Details and patient eligibility

About

The goal of this clinical trial is to evaluate the safety and efficacy of Formaderm Young Dermal Filler Injection, which is a hyaluronic acid dermal filler injected into the mid to deep dermis for the correction of moderate-to-severe nasolabial fold facial wrinkles.

The main questions it aims to answer are:

The differences of Wrinkle Severity Rating Scale (WSRS) after the injection.
The treatment improvement assessed by Global Aesthetic Improvement Scale (GAIS).
Safety Indicators of which incidences on the day of the injection or after the injection.

Participants will be blinded and randomized into either experiment group or control group, and re-visited on 1, 3, 6, 9 and 12 month after injection.

Researchers will compare if the test product is non-inferiority to Restylane.

Full description

A prospective, parallel, two-center, non-inferior, randomized, double-blind trial was conducted in this study. It was planned to recruit 157 subjects for each group, considering a 10% dropout rate that would lead to 320 subjects overall.

Subjects eligible in the screening will be enrolled. Each patient will receive the same treatment, either Formaderm Young Dermal Filler Injection or Restylane, to correct both sides of the nasolabial fold through randomization.

Clinical efficacy will be assessed by the blinded physician using the WSRS and GAIS, as well as by subjects using GAIS. The safety issue of Formaderm Young or Restylane will be identified and recorded during the course of the study.

Enrollment

320 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects are aged 18-65 years old of both sexes.
Subjects who are willing to undergo both sides nasolabial fold therapy.
The baseline measurement on the wrinkle severity rating scale (WSRS) should be 3-4 points, and the left and right sides should exhibit symmetry.
Willing to comply with re-visit schedule and sign the informed consent.

Exclusion criteria

Women subjects who are pregnant, breastfeeding, planning to become pregnant, and not willing to take contraception during the trial period.
Those who are emotionally unstable or suffering from a mental disease.
Those who have unhealthy facial skin or severe skin disease, inflammation, or related symptoms such as infections, psoriasis, herpes, and similar conditions.
Those with any disease that would interfere the assessment of skin aging.
Those who have a scar in the nasolabial fold area.
Those with connective tissue diseases.
Those with diabetes or systemic disease that cannot be controlled.
Those suffering from immunity related disorder.
Those with a scar-prone constitution.
Patients undergoing anticoagulant treatment, those who have a medical history of coagulation defects.
Patients taking antiplatelet medicine that could affect platelet function, such as Aspirin or non-steroidal anti-inflammatory analgesics.
Those with a allergy history of cosmetic filling agent, any type of hyaluronic acid implants or local anesthetic.
Those who have undergone facial cosmetic treatments or surgery before the trial:
Chemical or physical treatments that affect local configuration before the trial, such as laser procedures, skin resurfacing, chemical peel or Face Wrinkle Correction Surgery within 6 month.
Facial surgery or dermal filler at nasolabial fold area within 12 month.
Those who have cosmetic surgery with silicone in their body or material that cannot be absorbed by the body (permanent filling agent).
Those who are not willing to avoid undergoing other cosmetic treatment and surgery, such as facial filling, botulinum toxin Injection, laser procedures, chemical peel or facelift surgery.
Those who have participate in another clinical investigation within 12 month.
Those who are deemed unfit for inclusion.